Aquestive Therapeutics Inc. Company Profile
NASDAQ: AQSTHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
Aquestive Therapeutics at a glance
Aquestive Therapeutics Inc. (NASDAQ: AQST) is a Biotechnology: Pharmaceutical Preparations company in the Health Care sector headquartered in Warren, NJ. Aquestive Therapeutics is led by Mr. Daniel Barber and employs about 147 people. The company's shares have traded publicly since 2018.
At a market capitalization of $434.9 million, it is considered a small-cap company. Its SEC Central Index Key (CIK) is 0001398733, which identifies the company's filings on EDGAR.
Summary generated from market data by MetaCap's automated system. Methodology
What does Aquestive Therapeutics do?
Aquestive Therapeutics, Inc. operates as a pharmaceutical company in the United States and internationally. It offers Libervant, a buccal soluble film formulation of diazepam for the treatment of seizures; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; EMYLIF, an oral film formulation of riluzole; ONDIF, an oral soluble film formulation of ondansetron; SYMPAZAN, an oral soluble film formulation of clobazam used for the treatment of seizures associated with a rare, intractable form of epilepsy; KYNMOBI, a sublingual film formulation of apomorphine; and AZSTARYS, an fda-approved, once-daily product for the treatment of ADHD in patients age 6 years or older. The company's proprietary pipeline products include Anaphylm, an epinephrine sublingual film, which is in phase 3 clinical trial for the emergency treatment of allergic reactions, including anaphylaxis; and AQST-108, a topical gel that is in phase 2 clinical trial for the treatment of alopecia areata. In addition, it develops PharmFilm technology for patients suffering from certain central nervous system disorders; and Adrenaverse, an epinephrine prodrug platform. The company was incorporated in 2004 and is headquartered in Warren, New Jersey.
Business description based on the company's public filings.
Company information
- Legal name
- Aquestive Therapeutics Inc.
- Ticker
- NASDAQ: AQST
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- CEO
- Mr. Daniel Barber
- Employees
- 147
- Headquarters
- 184 Liberty Corner Road, Warren, NJ, United States
- Phone
- 908 941 1900
- Website
- aquestive.com
- IPO year
- 2018
- Market cap
- $434.88M
- SEC CIK
- 0001398733
Companies similar to Aquestive Therapeutics
| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| INDPIndaptus Therapeutics Inc. | 2.82 | -9.90% | $433.16M | vs AQST |
| EOLSEvolus Inc. | 6.52 | -6.86% | $431.55M | vs AQST |
| CAPRCapricor Therapeutics Inc. | 7.59 | +0.80% | $441.30M | vs AQST |
| LYELLyell Immunopharma Inc. | 13.80 | +1.62% | $441.82M | vs AQST |
| CTMXCytomX Therapeutics Inc. | 2.03 | -0.98% | $442.55M | vs AQST |
| AMRNAmarin Corporation plc | 10.57 | -6.13% | $444.39M | vs AQST |
| DMACDiaMedica Therapeutics Inc. | 8.25 | +2.87% | $445.15M | vs AQST |
| ARVNArvinas Inc. | 6.46 | -4.15% | $423.03M | vs AQST |